Massachusetts General Hospital

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Massachusetts General Hospital sits in the top decile of US sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count).

2,032 total trials 336 currently recruiting 1284 completed early-phase tilt top decile by trial count

Massachusetts General Hospital: 2,032 sponsored US clinical trials, 336 recruiting.

Massachusetts General Hospital sponsors 2,032 registered US clinical trials on ClinicalTrials.gov, 336 of them currently recruiting, and 1,284 completed. 240 of these trials are in Phase 3-4 (later-stage) and 515 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 29 trials.

Top-decile sponsor footprint

Massachusetts General Hospital ranks in the top decile of sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

2,032 total, page 31 of 41

TERMINATED NA

Does Percutaneous Tibial Nerve Stimulation (PTNS) Improve Outcomes in Patients Presenting With Fecal Incontinence

NCT01274585

COMPLETED NA

Could Meditation Modulate the Neurobiology of Learning Not to Fear?

NCT01320969

COMPLETED Phase 1

Study to Evaluate the Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) in Elderly Subjects

NCT01274598

COMPLETED NA

DAYLIGHT: Vitamin D Therapy in Individuals at High Risk of Hypertension

NCT01240512

COMPLETED NA

Effects of Growth Hormone Releasing Hormone in HIV

NCT01263717

COMPLETED Phase 2

Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma

NCT01239394

COMPLETED NA

A Novel Approach to Methicillin-resistant Staphylococcus Aureus (MRSA) Screening of Colonized Patients

NCT01234831

TERMINATED Phase 4

N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression

NCT01260649

COMPLETED NA

Efficacy and Safety of Cranial Electrical Stimulation (CES) for Major Depressive Disorder (MDD)

NCT01325532

COMPLETED Phase 4

Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders

NCT01631682

TERMINATED Phase 4

Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion

NCT01246011

COMPLETED NA

Individualized Stereotactic Body Radiotherapy of Liver Metastases

NCT01239381

COMPLETED NA

In-Room PET in Proton Radiation Therapy

NCT01228448

COMPLETED NA

Optical Frequency Domain Imaging (OFDI) Surveillance and Image Guided Biopsy of the Esophagus

NCT01439633

COMPLETED

Perception Prognosis, Goals of Treatment, and Communication

NCT01401894

COMPLETED NA

Be Fit in Residency: a Randomized Controlled Trial of an Activity Device Among Medicine Residents

NCT01287208

TERMINATED Phase 2

IPI-504 in NSCLC Patients With ALK Translocations

NCT01228435

COMPLETED Phase 1

An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

NCT01078961

COMPLETED Phase 4

Comparative Effectiveness Study for Bipolar Disorder

NCT01331304

COMPLETED NA

Vitamin D Deficiency in Adolescent Girls

NCT01180946

COMPLETED Phase 4

A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients

NCT01201967

TERMINATED Phase 2

Metformin in Castration-Resistant Prostate Cancer

NCT01215032

TERMINATED NA

Neuroimaging for Depression

NCT00864630

TERMINATED

Changes in Brown Adipose Tissue Activity In Men Receiving Androgen Deprivation Therapy for Prostate Cancer

NCT01226888

COMPLETED Phase 1

STA-9090 in Patients With Advanced Hepatocellular Cancer

NCT01665937

COMPLETED Phase 3

Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders

NCT01302964

COMPLETED Phase 1

Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

NCT01188876

COMPLETED Phase 2

Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention

NCT01188967

COMPLETED Phase 2

Tandem Auto-Allo Transplant for Lymphoma

NCT01181271

COMPLETED NA

Effectiveness of a Relaxation-Response Based Cognitive Behavioral Therapy Group for Depressed Chinese Patients

NCT01359839

COMPLETED Phase 2

STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer

NCT01167114

TERMINATED

Comparison of Xtreme CT and DXA Bone Densitometry

NCT01199991

COMPLETED NA

Impact of Vitamin D Supplementation on Cardiac Structure and Function

NCT01630213

COMPLETED NA

Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling

NCT01684943

COMPLETED NA

Effects of Blood Transfusion in Healthy Volunteers

NCT01226498

COMPLETED NA

Smoking Interventions for Hospital Patients

NCT01177176

COMPLETED NA

Emotion Regulation Group Therapy for Bipolar Disorder

NCT01207505

COMPLETED NA

Using Videos to Improve Understanding of the Delivery of End-of-life Medical Care in Non-hospital Settings

NCT01233973

TERMINATED Phase 2

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

NCT01173679

COMPLETED

Metabolic and Psychological Changes Associated With Menopause Among Women With HIV

NCT01142817

COMPLETED Phase 4

Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia

NCT01082588

COMPLETED Phase 4

Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots

NCT01149876

COMPLETED Phase 2

High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma

NCT01182415

COMPLETED

Effect of Spinal Cord Stimulation on Pain Thresholds and Sensory Perception in Chronic Pain Patients.

NCT01137617

TERMINATED NA

Ultrasound Method to Measure Fibrosis of the Liver in Children

NCT02086708

TERMINATED

Detailed Clinical, Biochemical and Genetic Characterization in Gonadotropin-releasing Hormone (GnRH) Deficiency Disorders

NCT01165619

COMPLETED NA

Stress Reduction and Anxiety: Effects on the Function and Structure of the Brain

NCT01128309

COMPLETED Phase 2

Pilot Study of Open-label Placebo to Treat Major Depressive Disorder

NCT01103271

COMPLETED NA

Computer Assisted Planing of Corrective Osteotomy for Distal Radius Malunion

NCT01193010

TERMINATED Phase 2

Effects of Estrogen and Hot Flashes on Mood in Postmenopausal Women

NCT01126801

← Previous Page 31 of 41 Next →

Phase Distribution

PhaseTrial count
Phase 1 226
Phase 2 289
Phase 3 58
Phase 4 182

What is open in the Massachusetts General Hospital pipeline

336 recruiting of 2,032 indexed (17% open); 1,284 completed (63%).

Phase mix: 240 late (III/IV) vs 515 early (I/II) (early-phase heavy).

Top condition: Depression (29 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.